Urocortin II inhibits the apoptosis of mesenteric arterial smooth muscle cells via L-type calcium channels in spontaneously hypertensive rats

Cellular Physiology and Biochemistry

Volumn 17, Issue 3-4, 2006, Pages 111-120

  Tao, Jin ^a,b   Zhang, Yuan ^a   Tuck, Wah Soong ^b   Li, Shengnan ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Apoptosis; L type calcium channels; Mesenteric arterial smooth muscle cells (MASMC); Urocortin (UCN) II; Whole cell patch clamp

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; ASTRESSIN 2B; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL STIMULATING AGENT; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; POTASSIUM CHLORIDE; UNCLASSIFIED DRUG; UROTENSIN II;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CALCIUM CURRENT; CONCENTRATION RESPONSE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG EFFECT; HYPOXIA; MALE; MESENTERIC ARTERY; NICK END LABELING; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; SPONTANEOUSLY HYPERTENSIVE RAT; WHOLE CELL;

ANIMALIA;

EID: 33645008924     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092072     Document Type: Article

References (33)

1. Martinez V, Wang L, Rivier JE, Vale W, Tache Y: Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: role of CRF receptor subtypes 1 and 2. J Pharmacol Exp Ther 2002;301:611-617.
2. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier J, Vale WW, Sawchenko PE: Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci 2001;98:2843-2848.
3. Takahashi K, Totsune K, Murakami O, Shibahara S: Urocortins as cardiovascular peptides. Peptides 2004;25:1723-1731.
4. Brar BK, Jonassen AK, Egorina EM, Chen A, Negro A, Perrin MH, Mjos OD, Latchman DS, Lee KF, Vale W: Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology 2004;145:24-35.
5. Chanalaris A, Lawrence KM, Stephanou A, Knight RD, Hsu SY, Hsueh A, Latchman DS: Protective effects of the urocortin homologues stresscopin (SCP) and stresscopin-related peptide (SRP) against hypoxia/reoxygenation injury in rat neonatal cardiomyocytes. J Mol Cell Cardiol 2003;35:1295-1305.
6. Brar BK, Stephanoul A, Knight R, Latchman DS: Activation of Protein Kinase B/Akt by Urocortin is Essential for its Ability to Protect Cardiac Cells Against Hypoxia/Reoxygenation-induced Cell Death. J Mol Cell Cardiol 2002;34:483-492.
7. Tao J, Xu H, Yang C, Liu CN, Li S: Effect of urocortin on L-type calcium currents in adult rat ventricular myocytes. Pharmacol Res 2004;50:471-476.
8. Cohen ML, Bloomquist W, Li D, Iyengar S: Effect of acute and subchronic subcutaneous urocortin on blood pressure and food consumption in ob/ob mice. Gen Pharmacol 2000;34:371-377.
9. Kageyama K, Furukawa K, Miki I, Terui K, Motomura S, Suda T: Vasodilative effects of urocortin II via protein kinase A and a mitogen-activated protein kinase in rat thoracic aorta. J Cardiovasc Pharmacol 2003;42:561-565.
10. Nishijo N, Takamine S, Sugiyama F, Kimoto K, Taniguchi K, Horiguchi H, Ogata T, Murakami, K, Fukamizu A, Yagami K: Vascular remodeling in hypertensive transgenic mice. Exp Anim 2001;48:203-208.
11. Mandegar M, Remillard CV, Yuan JX: Ion channels in pulmonary arterial hypertension. Prog Cardiovasc Dis 2002;45:81-114.
12. Guedes DN, Silva DF, Barbosa-Filho JM, Medeiros IA. Calcium antagonism and the vasorelaxation of the rat aorta induced by rotundifolone. Braz J Med Biol Res 2004;37:1881-1887.
13. Zhang Y, Gao Y, Zuo J, Lee R, Janssen LJ: Alteration of arterial smooth muscle potassium channel composition and BKCa current modulation in hypertension. Eur J Pharm 2005;514:111-119.
14. Pan SL, Guh JH, Chang YL, Kuo SC, Lee FY, Teng CM: YC-1 prevents sodium nitroprusside-mediated apoptosis in vascular smooth muscle cells. Cardiovas Res 2004;61:152-158.
15. Dautzenberg FM, Higelin J, Teichert U: Functional characterization of corticotropin-releasing factor type 1 receptor endogenously expressed in human embryonic kidney 293 cells. Eur J Pharmacol 2000;390:51-59.
16. v 1.2 calcium channels. J Biol Chem 2004;279:50329-50335.
17. Izumi T, Yamaguchi M: Overexpression of regucalcin suppresses cell death and apoptosis in cloned rat hepatoma H4-II-E cells induced by lipopolysaccharide, PD 98059, dibucaine, or Bay K 8644. J Cell Biochem 2004;93:598-608.
18. 2+ antagonists inhibit DNA fragmentation and toxic cell death induced by acetaminophen. FASEB J 1993;7:453-4563.
19. Scarabelli T, Knight R: Urocortins: take them to heart. Curr. Med. Chem. Cardiovasc. Hematol Agents 2004;2:335-342.
20. Chanalaris A, Lawrence KM, Townsend PA, Davidson S, Jamshidi Y, Stephanou A, Knight RD, Hsu SY, Hsueh AJ, Latchman DS: Hypertrophic effects of urocortin homologous peptides are mediated via activation of the Akt pathway. Biochem Biophys Res Commun 2005;328:442-448.
21. Nemoto T, Mano-Otagiri A, Shibasaki T: Urocortin 2 induces tyrosine hydroxylase phosphorylation in PC12 cells. Biochem Biophys Res Commun 2005;330:821-31.
22. Gibbons G.H: Endothelial function as a determinant of vascular function and structure: a new therapeutic target. Am J Cardiol 1997;79:3-8.
23. Kunigal S, Kusch A, Tkachuk N, Tkachuk S, Jerke U, Haller H, Dumler I: Monocyte-expressed urokinase inhibits vascular smooth muscle cell growth by activating Stat1. Blood 2003;102:4377-4383.
24. Sadeghi MM, Krassilnikova S, Zhang J, Gharaei AA, Fassaei HR, Esmailzadeh L, Kooshkabadi A, Edwards S, Yalamanchili P, Harris TD, Sinusas AJ, Zaret BL, Bender JR: Detection of injury-induced vascular remodeling by targeting activated alphavbeta3 integrin in vivo. Circulation 2004;110:84-90.
25. Catterall WA: Structure and function of voltage-Gated ion channels. Annu Rev Biochem 1995;64:493-531.
26. Li SN, Blaschke M, Heubach JF, Wettwer E, Ravens U: Effects of azelastine on contractility,action potentials and L-type Ca2+ currents in guinea-pig cardiac preparations. Eur J Pharmacol 2001;418:7-14.
27. Xu SZ, Zhang Y, Ren JY, Zhou ZN: Effects of berberine on L- and T-type calcium channels in guinea pig ventricular myocytes. Acta pharmacol Sin 1997;18:515-518.
28. Guo DL, Zhou ZN, Zheng FD, Hu CJ: Dauricine inhibited L-type calcium current in single cardiomyocyte of guinea pig. Acta pharmacol Sin 1997;18:419-421.
29. Liu CN, Yang C, Liu XY, Li SN: In vivo protective effects of urocortin on ischemia/reperfusion injury in rat heart via free radical mechanisms. Can J Physiol Pharmacol 2005;83:459-465.
30. Pereira LM, Bezerra DG, Mandarimde-Lacerda CA: Aortic wall remodeling in rats with nitric oxide deficiency treated by enalapril or verapamil. Pathol Res Pract 2004;200:211-217.
31. Tsatsanis C, Androulidaki A, Dermitzaki E, Charalampopoulos I, Spiess J, Gravanis A, Margioris AN: Urocortin 1 and Urocortin 2 induce macrophage apoptosis via CRFR2. FEBS Lett 2005;579:4259-4264.
32. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Lainchbury JG, Richards AM, Yamauchi N, Otagiri A, Nemoto T, Sekino A, Oono H, Kato I, Yanaihara C, Shibasaki T: Endogenous urocortins reduce vascular tone and renin-aldosterone/endothelin activity in experimental heart failure. Eur Heart J 2005;26:2046-2054.
33. Lawrence KM, Kabir A, Bellahcene M, Davidson S, Mesquita R, Cao X, McCormick J, Carroll CJ, Chanalaris A, Townsend PA, Hubank M, Stephanou A, Knight RA, Marber MS, Latchman DS: Cardioprotection mediated by urocortin is dependent upon PKCå activation. FASEB J 2005;19:831-833.